STMN1 promotes cell malignancy and bortezomib resistance of multiple myeloma cell lines via PI3K/AKT signaling
Article in Expert Opinion on Drug Safety (October 2023)
The most recent citing publications are shown below. View all 13 publications that cite this research output on Dimensions.
Article in Expert Opinion on Drug Safety (October 2023)
Article in Cellular Signalling (June 2023)
Article in Frontiers in Pharmacology (August 2022)